Transition Therapeutics Announces ELND005 Phase 2 Clinical Trial Data to be Presented at the International Conference of Alzheimer's Disease (ICAD) Meeting
Transition Therapeutics (Nasdaq: TTHI) announced today that data from the Phase 2 clinical trial of ELND005 in mild to moderate Alzheimer's disease patients will be presented at the International Conference on Alzheimer's Disease meeting, to be held July 16-21, 2011 in Paris, France. There will be two posters and one oral presentation covering safety, efficacy, imaging, biomarker and pharmacokinetic data from the Phase 2 clinical trial.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.